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INTRODUCTION 
With recent advances in biotechnology, it is now possible to synthesize a variety of 
valuable biologically active products from microbial sources. However, screening and 
economic recovery of these biosynthetically derived products poses a complex problem. 
The whole culture broth is an extremely heterogeneous aqueous mixture of biomass, 
nutrients, residual substrates, and other additives. In some cases, the desired product is 
generally present in very low concentrations (tO.l wt %) in this heterogeneous 
colloidal suspension. Also, bioproducts are usually unstable and are  prone to physical, 
chemical, or enzymatic degradation that limits the choice for separation and screening 
methods. 
We have chosen p-lactam antibiotics as a representative small molecular weight 
(MW < 1000) bioproduct for investigating the problems associated with screening and 
processing small molecular weight bioactive compounds. The design and the construc- 
tion of bioaffinity ligands and adsorbents for screening and processing whole culture 
broths containing j3-lactam antibiotics have been examined. An attempt will be made 
to generalize the results to draw conclusions about the feasibility of using this scheme 
for other bioactive materials. 
B-LACl'AM ANTIBIOTICS 
P-Lactams represent the largest group of commercially available antibiotics cur- 
rently in use. Penicillins and cephalosporins are the two major classes of p-lactam 
antibiotics produced by fungi. Research and development efforts involving screening of 
other microbial cells for &lactams have resulted in a boom of new discoveries in the 
past decade. Cephamycin was the first major @-lactam reported to be produced for 
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Streptomyces species rather than fungi. Following this discovery, a number of new 
p-lactam antibiotics were found through volume screening of actinomycetes in many 
laboratories. Most of the /?-lactam antibiotics produced by actinomycetes are structur- 
ally different penicillins and cephalosporins and are often referred to as nonclassic or 
atypical P-lactams (TABLE 1). Among the most exciting of these are a series of 
p-lactams designated as carbapenems. 
Carbapenems are the most potent of all the p-lactams known today. These 
compounds are characterized by an annealated five-membered ring containing a 
double bond. Thienamycin is the first and by far the most important member of this 
series.' Other members of the carbapenem family are epithienamycins, olivanic acids, 
PS-5, and carpetimycins. Most carbapenems display a broad spectrum of antimicro- 
bial activity covering a wide variety of gram-positive, gram-negative, and anaerobic 
bacteria. Other atypical @-lactams include oxapenems and penems, which are natural 
extensions of carbapenems. In these compounds, the carbon atom a t  the 1-position is 
replaced by an oxygen or a sulfur atom. Most of these nonclassic /3-lactams display an 
excellent resistance to degradation by a variety of 8-lactamases. They also act as strong 
p-lactam inhibitors in  the presence of substrates such as benzylpenicillin. We can 
safely assume that other, more potent p-lactams may exist in nature. 
The question, though, is whether new screening methods can be developed to isolate 
and discriminate these new antibiotics from the existing antibiotics. The discovery of 
nonclassic @-lactams was soon followed by attempts to develop bioseparation methods 
that were suitable for processing large quantities of fermentation broth. However, 
economic recovery of these antibiotics presents a fairly complex engineering problem. 
The whole fermentation broth is an extremely heterogeneous colloidal suspension 
consisting of proteinaceous materials, a variety of other macromolecules, particulate 
solids, and cells. The antibiotic concentration in the broth is usually extremely low 
(-5-10 pg/mL). Most of the nonclassic fi-lactams are stable only in low concentra- 
tions (< 1 .O mg/mL) and in narrow ranges of pH.'.* Kahan e f  al.' in their pioneering 
work reported production of thienarnycin in an overall recovery yield of less than 2%. 
Trieber et af.' subsequently reported an improved multistep process based on ion- 
exchange and reverse-phase chromatography. The overall yield by this process is still 
limited to 25-35%. The potential of ion-exchange chromatography for separation of 
thienamycin is quite limited due to the zwitterionic nature of the antibiotic. Further- 
more, various amino acids and small peptides in the broth that follow a protonation 
pattern similar to thienamycin also get adsorbed nonspecifically to the ion-exchange 
resin. Similar problems are encountered in attempts to isolate other nonclassic 
P - I a ~ t a m s . ~  
AFFINITY ADSORPTION 
Affinity adsorption due to its high degree of selectivity offers a promising alterna- 
tive in the initial steps of a conventional biochemical product recovery scheme. It is a 
separation technique based on specific and reversible binding using biological interac- 
tions. Affinity adsorption is now frequently used in the purification steps, but it is 
seldom used in processing more complex solutions such as fermentation broth. This is 
mainly because of the need to have relatively clean solution devoid of any suspended 
TABLE I. Representative &Lactam Antibiotics Produced in Actinomycetes 
Compound Structure Organism 
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solids, cell debris, or fouling proteins to perform affinity chromatography. Even a small 
fraction of solids carryover may lead to problems such as fouling and clogging of the 
affinity column, causing significant reduction in column performance.’ Mechanical 
properties of adsorbent particles and reduced product adsorption under the conditions 
of high Row rates further limit the utility of affinity chromatography for large-scale 
applications. 
One way of separating the bioproduct is by freely suspending the affinity adsorbent 
particles in  the whole fermentation broth. Adsorbent particles consist of biospecific 
ligands covalently attached to an inert, porous, solid support. Many problems are  
encountered in this approach. Large adsorbent particle size is required to ensure easy 
handling in the broth. However, this leads to high internal mass-transfer resistance, 
which in turn significantly reduces the adsorption rate. Moreover, the presence of 
various organic macromolecules can lead to rapid fouling of the adsorbent particles. 
This can introduce the problems of extensive product contamination and reduced 
effectiveness of the affinity adsorbent. Affinity ligand itself can undergo enzymatic or 
chemical degradation due to free contact with proteolytic enzymes and other contami- 
nants in the whole broth. The immobilized affinity adsorbents developed can poten- 
tially be used to isolate and screen new 8-lactams during the drug discovery program. 
We have been investigating the possibility of using affinity adsorbents entrapped in 
hydrogel beads or capsules for whole broth proce~sing.~,’ The hydrogel matrix can be 
provided by various reversible hydrogels. These hydrogels contain more than 95% 
water in their matrix. Consequently, additional resistance offered by the hydrogel 
matrix to the antibiotic diffusion is relatively insignificant. It is therefore possible to use 
relatively large beads or capsules (1-3 mm radius) to ensure easy recovery from the 
whole broth at  the end of the screening and separation processes. These hydrogels can 
be dissolved by removing the multivalent cations used for cross-linking or by inducing 
temperature shifts to recover the adsorbed bioproduct. Most of the macromolecules 
and the proteolytic enzymes present in the broth are excluded from the immobilized 
bead because of pore size restriction. Undesired macromolecules that do penetrate foul 
the outer layer first. Most of the ligand distributed inside remains uncontaminated and 
can be recycled for further use. Preliminary research conducted in our laboratory using 
immobilized adsorbents has indicated significant advantages in terms of high adsorp- 
tion rates, high selectivity, and reduced fouling characteristics.’ 
/3-LACTAMASE AS AFFINITY LIGAND 
P-Lactamases hydrolyze penicillins to produce penicilloates. Cephalosporates, on 
the other hand, are unstable in nature and decompose further. Most of the 8-lacta- 
mases produced by gram-positive bacteria are inducible or exocellular.’ 8-Lactamases 
produced by gram-negative microorganisms can be either inducible or constitutive. In 
gram-negative microorganisms, @-lactamases are usually periplasmic or cell bound.’ 
Several O-lactams have been reported to inhibit 8-lactamase activity. Two major types 
of 8-lactamase inhibitors have been identified: 
( 1 )  @-lactams that to some extent bind reversibly to block the active site of the 
enzyme and that display strong resistance to hydrolysis; 
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(2) 8-lactams that inhibit 8-lactamase activity by providing a competing substrate 
for the active site during the course of their normal hydrolytic reaction. 
Most of the nonclassic @-lactams such as carbapenems belong to the first category. 
However, they may sometimes display a combination of both mechanisms during the 
course of the binding reaction. 
The ability of p-lactams belonging to the first category to inhibit 8-lactamases 
without undergoing significant hydrolysis makes them ideally suited for affinity 
extraction from fermentation broths using 8-lactamase as the affinity ligand. Several 
research groups have recently reported cloning and expression of 8-lactamase genes in 
a variety of host cells.'0." Large amounts of 8-lactamase can be produced by these 
recombinant cells for use in production-scale separation applications. The enzyme can 
be separated and immobilized on a solid matrix such as controlled pore glass particles 
and it then can be entrapped in the hydrogel bead. Another possibility is to immobilize 
8-lactamase-producing cells directly in inert hydrogel beads or capsules, which will 
restrict the extracellular enzyme from leaking out into the broth. Immobilized cells can 
then be used as bioadsorbents for extracting p-lactam antibiotics directly from the 
broth. A major difficulty in using @-lactamases as affinity ligands is to elute the 
adsorbed antibiotic without hydrolyzing its active 8-lactam ring. The hydrolytic 
activity of the enzyme can be significantly reduced by operating at  low pH values (-4). 
However, our experience has indicated almost total degradation of the bound antibiotic 
even when extremely mild elution conditions such as shifts in pH or ionic strengths 
were employed.'* Similarly, several investigators have reported significant degradation 
of @-lactam antibiotics in the reverse situation where they were employed as affinity 
ligands to purify small quantities of 8-lactamase. 
PROTEIN ENGINEERING OF 8-LACTAMASE 
Recent advances in protein engineering techniques have raised the exciting possibil- 
ity of altering the amino acid sequence of this enzyme at  its active site by making 
site-specific mutations. Several researchers have recently reported the changes ob- 
served in the catalytic characteristics of 8-lactamase by effecting changes in the amino 
acid sequence at  its active site."-" The site-specific mutations can be used to "engineer" 
the enzyme such that it can only bind to the 8-lactam reversibly without hydrolyzing it. 
The altered enzyme can then be used as  an ideal ligand for affinity separation purposes. 
The nucleotide sequence and restriction mapping of @-lactamase has already been 
reported in the literature." This gene codes for a protein of 286 amino acid residues. 
The first 23 amino acids presumably form a signal for secretion because they do not 
appear to be in the mature enzyme whose partial amino acid sequence has been 
determined independently. The 3-D structure of Staphylococcal lactamase has been 
elucidated.16 A computer-generated model of 8-lactamase interacting with an ampicil- 
lin molecule is shown in FIGURE 1. Using various recombinant plasmids, 8-lactamase 
genes from Bacillus lichenijbrmis have been successfully cloned and expressed in E. 
coli, Bacillus subtilis, and Bacillus stearothermophilus."-" Excess 8-lactamase pro- 
duction has been observed in many cases. 8-Lactamase catalyzes the hydrolysis of the 
amide bond of the lactam ring of penicillins and related antibiotics. The catalytic 
pathway includes an acyl-enzyme intermediate. A serine residue probably participates 
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in catalysis. It is speculated that Ser-70 and Thr-71 probably form a conserved dyad. 
Site-specific mutagenesis has been used to invert the order of the dyad from Ser-Thr to 
Thr-Ser (i.e., a double mutation: Ser-70 - Thr and Thr - Ser). The mutant bacteria 
show no 8-lactamase activity, suggesting a functional defect in the enzyme.” Affinity 
extraction of P-lactam antibiotics that are resistant to the 0-lactamase requires the 
elucidation of the structure of the enzyme’s active site. Because the amino acid 
FIGURE 1. A computer-generated space filling model of the active site depression of j3-lacta- 
mase. The proposed site is bound with an ampicillin molecule. 
sequence of the 8-lactamase is known, a rational approach to develop affinity ligands 
for @-lactam antibiotic extraction is possible. 
The protein-engineered ligands were then used in subsequent experiments. In the 
initial phase, a gene bank of various 0-lactamases was collected and used in the 
experiments. Oligonucleotide-directed site-specific mutagenesis was used initially to 
change the primary structures of the 0-lactamases. The recombinant p-lactamases 
were tested for their ability to bind various p-lactams under different experimental 
conditions. Our initial success in developing first-generation recombinant proteins that 
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have these characteristics gives us the confidence that this is a viable approach.'* We 
are now investigating the use of j3-lactamase genes from Pseudornonas aeruginosa and 
other organisms that have much lower K, values than those of the ones from Bacillus 
spp. and are comparing their binding abilities. 
DEVELOPMENT OF MEMBRANE AFFINITY ADSORBENTS 
We have developed the use of membrane-encapsulated affinity and other semispe- 
cific adsorbents for directly extracting the bioproduct from the crude solutions, 
bypassing the solids removal Solid or liquid phase adsorbents can be encapsu- 
lated in membranes made of hydrogels such as calcium alginate, agarose, chitosan, or 
their mixtures (FIGURE 2). The membrane serves as a protective barrier against 
fouling. The membrane can also be used as a molecular sieve to increase the selectivity 
towards bioproducts having smaller molecular size by restricting the diffusion of larger 
contaminants. The membrane-encapsulated adsorbents can be directly contacted with 
crude solutions containing suspended solids. Due to their relatively large size (0.5-1.5 
mm diameter), encapsulated adsorbents can be easily retrieved from the crude solution 
by sieving or gravity settling. If continued or repeated use of encapsulated adsorbent 
leads to fouling of the protective membrane, the adsorbent material can be recovered 
by disrupting or dissolving the hydrogel membrane. Recovered adsorbent can be 
reencapsulated for further use. 
Three basic types of encapsulated affinity adsorbents can be prepared: 
(a) Membrane-encapsulated polymer/affinity ligand derivative: Affinity ligand (re- 
combinant j3-lactamase) can be bound to high molecular weight soluble poly- 
mers such as dextrans, polyethylene glycol, or polyacrylonitrile. These polymer 
ligand derivatives can be encapsulated in membrane capsules. 
(b) Membrane-encapsulated colloidal affinity ligand: It is possible to chemically fix 
cells of recombinant Bacillus stearotherrnophilus with overexpressed recombi- 
nant 0-lactamase. A suspension of these cells was membrane encapsulated to 
serve as affinity adsorbent for j3-lactam antibiotics (FIGURE 3). 
(c) Membrane-encapsulated porous support/affinity ligand derivative: Commercial 
. Gel Membrane Gel Matrix 
/ Adsorbent / 
FIGURE 2. Schematic drawings of various membrane-encapsulated affinity adsorbents used for 
screening and separation. 
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FIGURE 3. A microscopic photo- 
graph of membrane-encapsulated 
recombinant Bacillus stearothermo- 
philus that overexpresses 8-lacta- 
mase. These adsorbents have been 
used to isolate thienamycin from the 
fermentation broth.20 
affinity adsorbents containing recombinant B-lactamase covalently bound to 
various solid supports can be membrane encapsulated for use in crude solutions. 
A similar approach has been developed in our laboratories to isolate and purify 
Sruphylococcul protein A from cell homogenates.'6 
The optimization of batch adsorption time, capacity, and selectivity needs to be 
carried out by changing various design parameters of encapsulated adsorbents. A 
mathematical model similar to the one developed in reference 19 can be utilized in 
conjunction with experiments to relate the effect of different design parameters on 
binding kinetics, capacity, and selectivity. We are currently evaluating all of these 
possible designs of membrane-encapsulated protein-engineered enzymes and other 
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